(Q36219674)

English

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

phase II clinical trial

0 references

Jorge Eduardo Cortes

2

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

12 August 2017

PMC publication ID

Martin S. Tallman

4

object named as

Martin S Tallman

1 reference

Europe PubMed Central

12 August 2017

PMC publication ID

author name string

Jeffrey E Lancet

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Donna E Hogge

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Tibor J Kovacsovics

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Lloyd E Damon

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Rami Komrokji

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Scott R Solomon

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jonathan E Kolitz

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Maureen Cooper

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Andrew M Yeager

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Arthur C Louie

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Eric J Feldman

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

31 March 2014

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

123

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3239-3246

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Mouse models of human AML accurately predict chemotherapy response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

The incidence of secondary leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Effects of daunorubicin on cell growth, cell cycle and induction of apoptosis in HL-60 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

1 October 2017

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

22 September 2018

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624448

5 December 2018

Reasons for treating secondary AML as de novo AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687088

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2013-12-540971

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36219674&oldid=1981764637"